Cardinal Health stock analysis
Cardinal Health (CLH) Stock Price & Analysis
CLH Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 53.24B
- Enterprise Value
- CHF 55.55B
- Total Cash (Recent Filing)
- CHF 5.26B
- Total Debt (Recent Filing)
- CHF 8.81B
- Price to Earnings (P/E)
- 35.7
- Beta
- 1.44
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- 2.59
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.72%
Bulls Say, Bears Say
Bulls Say
Diversified Growth Platform
Growth across pharmaceuticals, specialty, at-Home, Nuclear & Precision Health, and OptiFreight reduces reliance on one operating area. Broad-based performance and investment across these businesses can support more durable revenue growth and provide multiple avenues for earnings expansion.
Long-term Customer Retention
Multi-year renewals with CVS and other major customers improve revenue visibility and reinforce Cardinal Health’s role in critical healthcare distribution. Retaining contracts across a large portion of enterprise revenue also supports scale, planning confidence, and longer-term operating stability.
Strong Cash Generation
Strong operating and free cash flow indicate that reported earnings are being converted into cash, supporting investment, debt service, and shareholder returns. High cash conversion gives management flexibility to fund strategic initiatives while maintaining financial resilience through the business cycle.
Bears Say
Negative Equity And Elevated Debt
Persistent negative equity leaves Cardinal Health’s capital structure more dependent on debt and continued operating stability. Although debt declined from the prior annual period, the combination reduces financial flexibility and could make deleveraging gradual even with strong cash generation.
Structurally Thin Margins
As a high-volume distributor, Cardinal Health converts a relatively small spread on very large revenue into profit. Thin margins leave earnings sensitive to pricing, product mix, volume, and execution pressure, making sustained profitability dependent on continued operating discipline.
Policy And Segment Headwinds
IRA-related reductions directly pressure pharmaceutical distribution revenue growth, while flat GMPD revenue shows weaker momentum in medical products and distribution. These factors may constrain mix and operating leverage, requiring continued growth in specialty and other businesses to offset pressure.
Cardinal Health News
CLH FAQ
What is Cardinal Health’s market cap?
When is Cardinal Health’s upcoming earnings report date?
How were Cardinal Health’s earnings last quarter?
Is Cardinal Health overvalued?
Does Cardinal Health pay dividends?
What is Cardinal Health’s EPS estimate?
How many shares outstanding does Cardinal Health have?
What happened to Cardinal Health’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Cardinal Health?
What is the TipRanks Smart Score and how is it calculated?
Cardinal Health Stock Smart Score
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Jason Hollar
- Employees
- 61,344
- Website
- www.cardinalhealth.com
- Address
- 7000 Cardinal Place, Dublin, OH, 43017, US
Cardinal Health (CLH) Earnings & Revenues
CLH Company Deck
CLH Earnings Call
Earnings Call SentimentPositive
The call was strongly positive. Cardinal Health reported broad-based first-quarter growth, significant operating leverage, 28% EPS growth, strong cash generation, major customer renewals, and raised full-year EPS and segment guidance. The main challenges were IRA-related WAC reductions, flat GMPD revenue, petroleum and other cost headwinds affecting GMPD profit, and expected moderation in earnings growth during the second and third quarters.
View all CH:CLH earnings summariesCLH Net sales Breakdown
- 91.94% Pharmaceutical and Specialty Solutions
- 5.68% Global Medical Products and Distribution
- 2.42% Other
- -0.04% Corporate
